CDKN2A and Miyoshi myopathy: Regarding the value of S100A4 compared to other known prognostic markers such as p16 and PD-L1, we previously showed a decreased relative expression of Cdkn2a (p16) in neoplastic relative to preneoplastic rat cell lines and in human MM cell lines relative to normal mesothelial cells [18].